HEALTH CARE DECISION MAKERS OPEN FOR PUBLIC AND PATIENT INVOLVEMENT IN COVERAGE DECISIONS

Published Apr 10, 2015
Brussels, Belgium – In a democratic system, politicians are elected to make decisions regarding health care priorities. In deliberation-driven systems, such as in Belgium, coverage decisions are based on the outcomes of a deliberation amongst stakeholders (including public authorities, providers, academics, and sickness funds). Patients and citizens are rarely –if-ever- directly involved in this process. Should citizens and patients be involved more intensively? If so, how?  To find out, researchers from the Belgian Health Care Knowledge Centre (KCE) performed a two-round Delphi survey on Belgian stakeholders currently involved or not (yet) involved in the decision-making processes. Eighty people participated in both rounds. The Delphi panel of participants consisted of politicians on national, regional and local level, members of advisory committees, patient organisations, and consumer organisations. Panel participants preferred citizens and patients to be consulted within the existing structures and at particular milestones in the process. Justification should be provided when decisions deviate from the recommendation of the public or patients. The researchers feel that further research is needed regarding the effectiveness of public and patient involvement strategies. Irina Cleemput, PhD, senior health economist, explains, “The panel reached consensus on the importance of public and patient involvement in health care coverage decisions, however, they see different roles for patients and citizens. While citizens should be involved in determining the general priorities in health care, patients should be involved in coverage decisions as experts by experience.” The full study, “Acceptability and Perceived Benefits and Risks of Public and Patient Involvement in Health Care Policy: A Delphi Survey in Belgian Stakeholders,” is published in Value in Health.

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Launches New Content on Whole Health

Sep 23, 2025

ISPOR announced that it has launched new website content on whole health, a topic of increasing importance as health systems across the globe grapple with providing the best possible healthcare to patients within constrained budgets.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×